How we support drug discovery research

CRUK-MEDI Alliance Laboratory

At Cancer Research UK (CRUK) we have a strong track record of therapeutic discovery. And thanks to our extensive portfolio of basic research and our strengths in drug development, we ensure that innovation in cancer treatment benefits patients sooner.

Cancer Research Horizons

We’re changing our approach to drug discovery and commercialisation with the launch of our innovation engine, Cancer Research Horizons, to ensure the research we fund has the best chance of reaching cancer patients.

An integral part of Cancer Research Horizons is our exciting and ambitious approach to driving therapeutic innovation. We're uniting the strengths of our established drug discovery engines, our network of world-class biology researchers, cutting-edge technology platforms and clinical expertise.

Immuno-oncology Alliance with Ono Pharma and LifeArc

Our alliance engages with academic researchers to accelerate the translation of discovery science to new immunotherapies. If you're a researcher working in the immuno-oncology space and have identified a potential target or a platform technology for target identification, we'd love to hear from you.


Our new funding opportunity, the Therapeutic Catalyst, will accelerate the translation of laboratory discoveries into novel cancer therapeutics in collaboration with CRUK drug discoverers. The partnership will utilise the expertise of both the researcher and CRUK drug discoverers to accelerate early therapeutic opportunities. We strongly encourage researchers with novel insights into cancer biology that can be targeted therapeutically to treat cancer to apply for this new opportunity.


Our Therapeutic Discovery awards, including the Therapeutic Discovery Pilot Award, the Therapeutic Discovery Project Award, and the Therapeutic Discovery Programme Award are currently on pause.

Where next for cancer immunotherapy?

Where next for cancer immunotherapy?

We're driving discovery research in immuno-oncology which is leading to novel and exciting immunotherapeutic possibilities.

Beating cancer from within

Find out why we’re investing in a platform for immunotherapy

Read the full story